Machado-Alba Jorge Enrique, Calvo-Torres Luis Felipe, Gaviria-Mendoza Andrés, Castrillón-Spitia Juan Daniel
Grupo de Investigación en Farmacoepidemiología y Farmacovigilancia, Universidad Tecnológica de Pereira-Audifarma, S.A., Pereira, Colombia.
Biomedica. 2018 Sep 1;38(3):417-426. doi: 10.7705/biomedica.v38i4.3781.
Parkinson's disease, whose prevalence in Colombia is 4.7 per 1,000 inhabitants, is a public health problem and a therapeutic challenge for health professionals.
To determine the prescribing patterns of antiparkinson drugs and the variables associated with its use in a population from Colombia.
We conducted a descriptive cross-sectional study. We selected patients who had been given antiparkinson drugs uninterruptedly between January 1st and March 31st, 2015 from a systematized database of approximately 3.5 million people affiliated to the Colombian health system. We included sociodemographic, pharmacologic and comedication variables. For the multivariate analysis, we used the IBM SPSS™-22 software.
A total of 2,898 patients was included; the mean age was 65.1years, and 50.7% were men; 69.4% (n=2010) of people received monotherapy and 30.6% combination therapy with two to five antiparkinson drugs. The most frequently prescribed drugs were: levodopa 45.5% (n=1,318 patients), biperiden 23.1% (670), amantadine 18.3% (531) and pramipexole 16.3% (471). The most commonly used association was levodopa/carbidopa + entacapone (n=311; 10.7%). Multivariate analysis showed that being male (OR=1.56; 95%CI: 1.321-1.837), over 60 years (OR=1.41; 95%CI 1.112-1.782) and receiving treatment in the city of Barranquilla (OR=2.23; 95%CI 1.675-2.975) were statistically associated with a greater risk of using combination therapy; 68.2% (n=1,977) patients were given concomitant treatment with other drugs.
Prescribing habits of drugs with high therapeutic value predominated, mainly in antiparkinson drugs monotherapy. Most were employed in the usual recommended doses. It is necessary to explore the clinical effectiveness of the medications studied and differentiate between disease and parkinsonian syndromes subtypes.
帕金森病在哥伦比亚的患病率为每1000名居民中有4.7人患病,它是一个公共卫生问题,对卫生专业人员来说也是一项治疗挑战。
确定哥伦比亚人群中抗帕金森药物的处方模式及其使用相关变量。
我们开展了一项描述性横断面研究。我们从哥伦比亚卫生系统约350万人的系统化数据库中选取了在2015年1月1日至3月31日期间持续接受抗帕金森药物治疗的患者。我们纳入了社会人口统计学、药理学和合并用药变量。对于多变量分析,我们使用了IBM SPSS™ - 22软件。
共纳入2898名患者;平均年龄为65.1岁,男性占50.7%;69.4%(n = 2010)的人接受单一疗法,30.6%接受两种至五种抗帕金森药物的联合疗法。最常处方的药物为:左旋多巴45.5%(n = 1318例患者)、安克痉23.1%(670例)、金刚烷胺18.3%(531例)和普拉克索16.3%(471例)。最常用的联合用药是左旋多巴/卡比多巴 + 恩他卡朋(n = 311;10.7%)。多变量分析显示,男性(OR = 1.56;95%CI:1.321 - 1.837)、60岁以上(OR = 1.41;95%CI 1.112 - 1.782)以及在巴兰基亚市接受治疗(OR = 2.23;95%CI 1.675 - 2.975)与使用联合疗法的风险更高在统计学上相关;68.2%(n = 1977)的患者同时接受其他药物治疗。
具有高治疗价值药物的处方习惯占主导,主要是抗帕金森药物单一疗法。大多数药物按通常推荐剂量使用。有必要探索所研究药物的临床疗效,并区分疾病和帕金森综合征亚型。